Trial Profile
Phase I Study of Pembrolizumab in Combination With Ibrutinib in the Treatment of Unresectable or Metastatic Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 19 Sep 2023 Planned End Date changed from 1 Dec 2024 to 31 Dec 2024.
- 19 Sep 2023 Planned primary completion date changed from 1 Dec 2023 to 31 Dec 2024.
- 13 Jan 2023 Planned primary completion date changed from 1 Feb 2023 to 1 Dec 2023.